Correspondence 0001104659-25-006763 from Evaxion A/S (EVAX)
Evaxion A/S
Date: Jan. 28, 2025 · CIK: 0001828253 · Accession: 0001104659-25-006763
AI Filing Summary & Sentiment
File numbers found in text: 333-283304
Letter
Office of Life Sciences Division of Corporation Finance Registration Statement on Form F-1 (File No. 333-283304) Acceleration Request Requested Date: January 29, 2025 Requested Time: 5:00 P.M. Eastern Time
Dear Mr. Howes:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form F-1 (File No. 333-283304) (the “Registration Statement”) to become effective on Wednesday, January 29, 2025, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff (the “Staff”).
Once the Registration Statement has been declared effective, please orally confirm that event with Michael D. Baird of Duane Morris LLP by telephone at (215) 870-6771, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
The Company understands that the Staff will consider this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the offering of the securities covered by the Registration Statement.
Very truly yours,
Evaxion Biotech A/S
Show Raw Text
CORRESP
1
filename1.htm
Evaxion Biotech A/S
Dr. Neergaards
Vej 5F
2970 Hørsholm
Denmark
Telephone: +45 31 31
97 53
January 28, 2025
U.S. Securities and Exchange Commission
Office of Life Sciences
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4546
Washington, D.C. 20549
Attn:
Mr. Tyler Howes
Re: Evaxion Biotech A/S
Registration Statement on Form F-1 (File
No. 333-283304)
Acceleration Request
Requested Date: January 29, 2025
Requested Time: 5:00 P.M. Eastern Time
Dear Mr. Howes:
In accordance with Rule 461 of
Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned registrant (the
“Registrant”) hereby requests that the Securities and Exchange Commission (the
“Commission”) take appropriate action to cause the above-referenced Registration Statement on
Form F-1 (File No. 333-283304) (the “Registration Statement”) to become effective on Wednesday,
January 29, 2025, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as the Registrant or its
counsel may orally request via telephone call to the staff (the “Staff”).
Once the Registration Statement has been declared
effective, please orally confirm that event with Michael D. Baird of Duane Morris LLP by telephone at (215) 870-6771, or if you have any
questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
The Company understands that the Staff will consider
this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate
to the offering of the securities covered by the Registration Statement.
Very truly yours,
Evaxion Biotech A/S
By:
/s/ Christian Kanstrup
Christian Kanstrup
Chief Executive Officer
cc:
Michael D. Baird, Duane Morris LLP
Lars
Lüthjohan Jensen, Mazanati-Andersen
2